ArticleThe Journal of experimental medicine2018
Sustained Id2 regulation of E proteins is required for terminal differentiation of effector CD8
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 87 citations in OpenAlex.
- Article
- Exhausted CD8Nature immunology · 2026Article
- Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Jump-starting the T cell response in established tumors.bioRxiv : the preprint server for biology · 2026Article
- Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting.Frontiers in immunology · 2026Review
- Article
- Atomistic TCR-ligand interactions instruct memory T-cell differentiation.bioRxiv : the preprint server for biology · 2025Article
- Unraveling the causal role of TGF-βRII in osteoporosis and the potential of its associated differential genes as novel targets.European journal of medical research · 2025Article
- Engineering resilient CAR T cells for immunosuppressive environment.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- The epigenetic landscape of fate decisions in T cells.Nature immunology · 2025Review
- Id2 exacerbates the development of rheumatoid arthritis by increasing IFN-γ production in CD4Clinical and translational medicine · 2025Article
- Innateness transcriptome gradients characterize mouse T lymphocyte populations.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- DELVE: feature selection for preserving biological trajectories in single-cell data.Nature communications · 2024Article
- Id2 epigenetically controls CD8Cellular & molecular immunology · 2024Article
- BATF and BATF3 deficiency alters CD8+ effector/exhausted T cells balance in skin transplantation.Molecular medicine (Cambridge, Mass.) · 2024Article
- Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy.Frontiers in immunology · 2024Review
- Location versus ID: what matters to lung-resident memory T cells?Frontiers in immunology · 2024Article
- FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells.Nature immunology · 2024Article
- Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan.Nature immunology · 2023Article
- Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors.Cell reports. Medicine · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.